Next Article in Journal
Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties
Next Article in Special Issue
Aerosol of Enoximone/Hydroxypropyl-β-Cyclodextrin Inclusion Complex, Biopharmaceutical Evidence for ARDS Applicability
Previous Article in Journal
Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer
Previous Article in Special Issue
A Novel Inhalable Dry Powder to Trigger Delivery of Voriconazole for Effective Management of Pulmonary Aspergillosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 16
Issue 8
10.3390/pharmaceutics16080980
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dry Powder Inhaler Formulation of Lactobacillus rhamnosus GG Targeting Pseudomonas aeruginosa Infection in Bronchiectasis Maintenance Therapy

by
The-Thien Tran
1,
Wean Sin Cheow
2,
Siyu Pu
1,
Jin-Won Park
3 and
Kunn Hadinoto
1,*
1
School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University Singapore, Singapore 637459, Singapore
2
Singapore Institute of Technology, Singapore 138683, Singapore
3
Department of Chemical and Biomolecular Engineering, Seoul National University of Science and Technology, Seoul 01811, Republic of Korea
*
Author to whom correspondence should be addressed.
Pharmaceutics 2024, 16(8), 980; https://doi.org/10.3390/pharmaceutics16080980
Submission received: 11 June 2024 / Revised: 15 July 2024 / Accepted: 22 July 2024 / Published: 25 July 2024
(This article belongs to the Special Issue Inhalable Drugs for the Treatment of Chronic Respiratory Diseases)
Browse Figures
Versions Notes

Abstract

The inhaled delivery of lactic acid bacteria (LAB) probiotics has been demonstrated to exert therapeutic benefits to the lungs due to LAB’s immunomodulatory activities. The development of inhaled probiotics formulation, however, is in its nascent stage limited to nebulized LAB. We developed a dry powder inhaler (DPI) formulation of lactobacillus rhamnosus GG (LGG) intended for bronchiectasis maintenance therapy by spray freeze drying (SFD). The optimal DPI formulation (i.e., LGG: mannitol: lactose: leucine = 35: 45: 15: 5 wt.%) was determined based on the aerosolization efficiency (86% emitted dose and 26% respirable fraction) and LGG cell viability post-SFD (7 log CFU/mL per mg powder). The optimal DPI formulation was evaluated and compared to lyophilized naked LGG by its (1) adhesion capacity and cytotoxicity to human lung epithelium cells (i.e., A549 and 16HBE14o- cells) as well as its (2) effectiveness in inhibiting the growth and adhesion of Pseudomonas aeruginosa to lung cells. The optimal DPI of LGG exhibited similar non-cytotoxicity and adhesion capacity to lung cells to naked LGG. The DPI of LGG also inhibited the growth and adhesion of P. aeruginosa to the lung cells as effectively as the naked LGG. The present work established the feasibility of delivering the LAB probiotic by the DPI platform without adversely affecting LGG’s anti-pseudomonal activities.
Keywords: dry powder inhaler; pulmonary drug delivery; lung infection; probiotics dry powder inhaler; pulmonary drug delivery; lung infection; probiotics

Share and Cite

MDPI and ACS Style

Tran, T.-T.; Cheow, W.S.; Pu, S.; Park, J.-W.; Hadinoto, K. Dry Powder Inhaler Formulation of Lactobacillus rhamnosus GG Targeting Pseudomonas aeruginosa Infection in Bronchiectasis Maintenance Therapy. Pharmaceutics 2024, 16, 980. https://doi.org/10.3390/pharmaceutics16080980

AMA Style

Tran T-T, Cheow WS, Pu S, Park J-W, Hadinoto K. Dry Powder Inhaler Formulation of Lactobacillus rhamnosus GG Targeting Pseudomonas aeruginosa Infection in Bronchiectasis Maintenance Therapy. Pharmaceutics. 2024; 16(8):980. https://doi.org/10.3390/pharmaceutics16080980

Chicago/Turabian Style

Tran, The-Thien, Wean Sin Cheow, Siyu Pu, Jin-Won Park, and Kunn Hadinoto. 2024. "Dry Powder Inhaler Formulation of Lactobacillus rhamnosus GG Targeting Pseudomonas aeruginosa Infection in Bronchiectasis Maintenance Therapy" Pharmaceutics 16, no. 8: 980. https://doi.org/10.3390/pharmaceutics16080980

APA Style

Tran, T.-T., Cheow, W. S., Pu, S., Park, J.-W., & Hadinoto, K. (2024). Dry Powder Inhaler Formulation of Lactobacillus rhamnosus GG Targeting Pseudomonas aeruginosa Infection in Bronchiectasis Maintenance Therapy. Pharmaceutics, 16(8), 980. https://doi.org/10.3390/pharmaceutics16080980

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop